Pulmonx Corporation Share Price

Equities

LUNG

US7458481014

Medical Equipment, Supplies & Distribution

Market Closed - Nasdaq 21:00:00 12/07/2024 BST 5-day change 1st Jan Change
7.42 USD +2.63% Intraday chart for Pulmonx Corporation +14.33% -41.80%
Sales 2024 * 82.6M 6.36B Sales 2025 * 98.17M 7.56B Capitalization 288M 22.18B
Net income 2024 * -65M -5.01B Net income 2025 * -61M -4.7B EV / Sales 2024 * 3.49 x
Net cash position 2024 * - 0 Net cash position 2025 * - 0 EV / Sales 2025 * 2.93 x
P/E ratio 2024 *
-4.43 x
P/E ratio 2025 *
-4.75 x
Employees 279
Yield 2024 *
-
Yield 2025 *
-
Free-Float 94.74%
More Fundamentals * Assessed data
Dynamic Chart
1 day+2.63%
1 week+14.33%
Current month+17.03%
1 month+18.63%
3 months-5.96%
6 months-41.71%
Current year-41.80%
More quotes
1 week
6.25
Extreme 6.25
7.45
1 month
5.67
Extreme 5.67
7.45
Current year
5.67
Extreme 5.67
14.84
1 year
5.67
Extreme 5.67
14.84
3 years
4.07
Extreme 4.07
45.49
5 years
4.07
Extreme 4.07
69.48
10 years
4.07
Extreme 4.07
69.48
More quotes
Managers TitleAgeSince
Chief Tech/Sci/R&D Officer - -
Chief Tech/Sci/R&D Officer - 31/12/07
Chief Administrative Officer - 31/12/08
Members of the board TitleAgeSince
Director/Board Member 70 31/01/07
Director/Board Member 62 17/12/14
Chairman 64 31/01/10
More insiders
Date Price Change Volume
12/07/24 7.42 +2.63% 182,153
11/07/24 7.23 +13.86% 256,168
10/07/24 6.35 -0.63% 141,133
09/07/24 6.39 -0.93% 141,249
08/07/24 6.45 -0.62% 188,956

Delayed Quote Nasdaq, July 12, 2024 at 09:00 pm

More quotes
Pulmonx Corporation is a commercial-stage medical technology company. The Company provides a minimally invasive treatment for patients with severe emphysema, a form of chronic obstructive pulmonary disease. Its solutions, which is comprised of the Zephyr Endobronchial Valve (Zephyr Valve), the Chartis Pulmonary Assessment System (Chartis System) and the StratX Lung Analysis Platform (StratX Platform), is designed to treat severe emphysema patients. The StratX Platform is a cloud-based quantitative CT analysis service that offers physicians with a report that is designed for its solution, which includes information on emphysema destruction, fissure completeness and lobar volume to help identify target lobes for treatment with Zephyr Valves. The Chartis System is a balloon catheter and console system with flow and pressure sensors designed to assess the presence of collateral ventilation and has been validated in multiple randomized controlled clinical trials.
Calendar
Related indices
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
C-
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
6
Last Close Price
7.42 USD
Average target price
14.83 USD
Spread / Average Target
+99.91%
Consensus